These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21310910)

  • 21. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
    Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
    Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB; Tao Y; Rensch F
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract]   [Full Text] [Related]  

  • 25. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS; Custis P; Howes J; Hsu JW
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML; Abedi G; Ness S; Ahmed E; Fenberg M; Daly MK; Houranieh A; Feinberg EB
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study.
    Potter MJ; Claudio CC; Szabo SM
    Br J Ophthalmol; 2010 Feb; 94(2):174-9. PubMed ID: 19520690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased electroretinogram a-wave amplitude after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Skaat A; Solomon A; Moroz I; Hai OV; Rechtman E; Vishnevskia Dai V; Rotenstreich Y
    Acta Ophthalmol; 2011 May; 89(3):e269-73. PubMed ID: 20946333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
    Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
    Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
    Kumar A; Sahni JN; Stangos AN; Campa C; Harding SP
    Br J Ophthalmol; 2011 Apr; 95(4):530-3. PubMed ID: 20937739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
    Campa C; Hagan R; Sahni JN; Brown MC; Beare NA; Heimann H; Harding SP
    Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3446-51. PubMed ID: 21357390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
    Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.